Investment in the Future of Biotech
Join Us in Advancing Breakthrough Therapies to the Clinic and Driving the Fight Against Muscular Dystrophy.
Investment Opportunity
Sarcomatrix presents a unique investment opportunity in the rare disease space, leveraging industry-leading research and a novel therapeutic platform. Our multifaceted development approach, portfolio of therapies, and “green field” intellectual property position offer significant potential.
Current Funding Round
Sarcomatrix is currently raising a $5M Seed+ round under a Regulation D 506(c) exemption. To date, we’ve secured $500,000 in equity-based funding, with an additional $1M soft circled. We also have a commitment letter for matching funds from the Battle Born Venture Fund. This offering is open only to verified accredited investors. If interested, please contact us for more information and verification requirements.
Non-Dilutive Funding
We have secured significant non-dilutive funding, including $8M in NIH grants for preclinical research on S-969.
Use of Seed+ Funds
The $5M Seed+ funding will be used to advance our preclinical programs, prepare the IND package, and initiate Phase 1 human clinical trials.
Future Funding
We plan a larger Series A raise to advance our programs towards NDA filing.
Investor Appeal & Challenges
Sarcomatrix offers a compelling opportunity with its platform technology, multiple therapeutic assets, and strong intellectual property position. While we recognize the current investment climate is challenging and that our stage may be considered early for some, early-stage biotech investments are historically associated with high risk—and high potential reward—for investors positioned at the forefront of innovation.
Resources for Investors
A non-confidential pitch deck is available for initial review. Investor updates are provided regularly, and access to our virtual data room can be granted upon execution of a non-disclosure agreement (NDA).
Financial Strategy
Our financial strategy involves careful management of expenses, strategic R&D investments, and the continued pursuit of non-dilutive funding opportunities. Sarcomatrix is currently pre-revenue.
